[go: up one dir, main page]

MX2018000539A - Inhibidores de il-8 para utilizarse en el tratamiento de ciertos trastornos urologicos. - Google Patents

Inhibidores de il-8 para utilizarse en el tratamiento de ciertos trastornos urologicos.

Info

Publication number
MX2018000539A
MX2018000539A MX2018000539A MX2018000539A MX2018000539A MX 2018000539 A MX2018000539 A MX 2018000539A MX 2018000539 A MX2018000539 A MX 2018000539A MX 2018000539 A MX2018000539 A MX 2018000539A MX 2018000539 A MX2018000539 A MX 2018000539A
Authority
MX
Mexico
Prior art keywords
treatment
inhibitors
urological disorders
oab
pbs
Prior art date
Application number
MX2018000539A
Other languages
English (en)
Inventor
Allegretti Marcello
Aramini Andrea
Candida Cesta Maria
Angelico Patrizia
Bianchini Gianluca
Brandolini Laura
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of MX2018000539A publication Critical patent/MX2018000539A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a compuestos inhibidores de IL-8, de preferencia inhibidores dobles de los receptores CXCR1/CXCR2, útiles en el tratamiento y/o en la prevención de cistitis intersticial/síndrome de vejiga dolorosa (IC/PBS) y/o vejiga sobreactiva (OAB), también incluyendo cistitis intersticial/síndrome de vejiga dolorosa (IC/PBS) y/o vejiga sobreactiva (OAB) inducida por la terapia contra el cáncer. También se cubren en la misma los métodos para el tratamiento y/o la prevención, y las combinaciones y kits que comprenden dichos inhibidores de lL-8.
MX2018000539A 2015-07-14 2016-07-12 Inhibidores de il-8 para utilizarse en el tratamiento de ciertos trastornos urologicos. MX2018000539A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15176726.6A EP3117835A1 (en) 2015-07-14 2015-07-14 Il-8 inhibitors for use in the treatment of certain urological disorders
PCT/EP2016/066511 WO2017009323A1 (en) 2015-07-14 2016-07-12 Il-8 inhibitors for use in the treatment of certain urological disorders

Publications (1)

Publication Number Publication Date
MX2018000539A true MX2018000539A (es) 2018-09-06

Family

ID=53757997

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000539A MX2018000539A (es) 2015-07-14 2016-07-12 Inhibidores de il-8 para utilizarse en el tratamiento de ciertos trastornos urologicos.

Country Status (25)

Country Link
US (2) US12150933B2 (es)
EP (2) EP3117835A1 (es)
JP (1) JP6937738B2 (es)
KR (1) KR102622924B1 (es)
CN (1) CN107921105B (es)
AU (1) AU2016292902B2 (es)
CA (1) CA2991810C (es)
CY (1) CY1125437T1 (es)
DK (1) DK3322438T3 (es)
EA (2) EA201890312A1 (es)
ES (1) ES2894077T3 (es)
HR (1) HRP20211574T1 (es)
HU (1) HUE056439T2 (es)
IL (1) IL256413B (es)
LT (1) LT3322438T (es)
MA (1) MA42437A (es)
MD (1) MD3322438T2 (es)
MX (1) MX2018000539A (es)
PL (1) PL3322438T3 (es)
PT (1) PT3322438T (es)
RS (1) RS62413B1 (es)
SI (1) SI3322438T1 (es)
SM (1) SMT202100582T1 (es)
WO (1) WO2017009323A1 (es)
ZA (1) ZA201708608B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3342407A1 (en) * 2017-01-03 2018-07-04 Dompé farmaceutici S.p.A. Il-8 inihibitors for use in the treatment of some urological disorders
EP3409277A1 (en) 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
CN114712377B (zh) * 2022-04-26 2023-08-15 江苏师范大学 断血流皂苷a在制造药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体拮抗剤
TW200530231A (en) 2003-12-22 2005-09-16 Schering Corp Isothiazole dioxides as CXC-and CC-chemokine receptor ligands
AU2005223402B2 (en) 2004-03-23 2011-07-21 Dompe' Farmaceutici S.P.A. 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
KR101458947B1 (ko) * 2013-03-05 2014-11-12 국립암센터 인터루킨-８ 앱타머 및 이의 용도

Also Published As

Publication number Publication date
PL3322438T3 (pl) 2022-01-03
WO2017009323A1 (en) 2017-01-19
EA202190242A1 (ru) 2021-11-30
KR20180030075A (ko) 2018-03-21
IL256413B (en) 2021-04-29
HRP20211574T1 (hr) 2022-02-04
EP3322438B1 (en) 2021-09-08
MA42437A (fr) 2021-06-02
SI3322438T1 (sl) 2021-11-30
MD3322438T2 (ro) 2022-01-31
CA2991810A1 (en) 2017-01-19
JP6937738B2 (ja) 2021-09-22
EP3117835A1 (en) 2017-01-18
US20250032461A1 (en) 2025-01-30
IL256413A (en) 2018-02-28
ES2894077T3 (es) 2022-02-11
US12150933B2 (en) 2024-11-26
JP2018520184A (ja) 2018-07-26
BR112018000676A2 (pt) 2018-09-18
CY1125437T1 (el) 2023-03-24
ZA201708608B (en) 2019-05-29
CA2991810C (en) 2025-05-27
RS62413B1 (sr) 2021-10-29
EA201890312A1 (ru) 2018-08-31
PT3322438T (pt) 2021-10-01
US20180200231A1 (en) 2018-07-19
SMT202100582T1 (it) 2021-11-12
HUE056439T2 (hu) 2022-02-28
EP3322438A1 (en) 2018-05-23
LT3322438T (lt) 2021-10-25
NZ739077A (en) 2023-12-22
KR102622924B1 (ko) 2024-01-09
AU2016292902B2 (en) 2021-06-03
DK3322438T3 (da) 2021-10-18
AU2016292902A1 (en) 2018-01-18
CN107921105B (zh) 2022-08-02
CN107921105A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
MX377273B (es) Ciclopropilamina como inhibidor de la desmetilasa 1 específica de lisinas (lsd1).
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
MX373154B (es) Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
MX2021006734A (es) Metodo para tratar el cancer.
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
UY36153A (es) ?inhibidores de la fosfoinosítido 3-quinasa delta para su uso en el tratamiento de una enfermedad cutánea inmunoampollosa mediada por autoanticuerpos?
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
EA201790737A1 (ru) Комбинированная терапия
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MX385762B (es) Métodos para el control transcripcional objetivo en regiones del super mejorador.
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
EA201692470A1 (ru) Фармацевтические комбинации
MX2019007892A (es) Compuestos inhibidores de metaloenzimas.
EA201792610A1 (ru) Способ лечения неврологического заболевания
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX383254B (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX388815B (es) Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.